GSK, Spero report Phase 3 win for UTI antibiotic; Spero's stock soars
GSK and Spero Therapeutics announced that a Phase 3 trial for their complicated UTI antibiotic reached its primary endpoint, setting up a potential FDA decision …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
